Results 31 to 40 of about 28,388 (258)

Engineering CAR‐Macrophages With Advanced Delivery Systems for Tissue Repair

Advanced Science, EarlyView.
This review highlights how engineered macrophages equipped with chimeric antigen receptors (CAR) guide tissue repair by recognizing disease‐related targets, clearing harmful cells, and reshaping local immune environments. It summarizes macrophage biology, CAR design, delivery platforms, and functionalization strategies, and discusses emerging ...
Yixin Zhang, Jintian Yu, Liang Yuan, Ziliang Fu, Yiming Yao, Lingna Chen, Shixiong Chen, Aikemu Ainiwaer, Xiaolin Cui   +8 more
wiley   +1 more source

Dipeptidyl peptidase-4 inhibitor-related renal disease

Journal of Diabetes and its Complications, 2023
Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used to treat type 2 diabetes (T2D). Lowering blood glucose is expected also to reduce the progression of diabetic nephropathy. We experienced a patient with T2D who achieved good glycemic control with a DPP-4 inhibitor but experienced rapid deterioration of renal function.
Atsuhiko, Suenaga, Naoki, Sawa, Yuki, Oba, Daisuke, Ikuma, Akinari, Sekine, Eiko, Hasegawa, Hiroki, Mizuno, Tatsuya, Suwabe, Sara, Ikeda, Tetsuro, Tsujimoto, Kei, Kono, Yukako, Shintani-Domoto, Keiichi, Kinowaki, Kenichi, Ohashi, Motoaki, Miyazono, Yutaka, Yamaguchi, Yoshifumi, Ubara   +16 more
openaire   +2 more sources

The Antidiabetic Potential of Alpha‐Mangostin: A Review of Preclinical and Clinical Evidence

AgriFood: Journal of Agricultural Products for Food, EarlyView.
Alpha‐mangostin is a compound from the pericarp of Garcinia mangostana. The antidiabetic effects of alpha‐mangostin include enhancing insulin secretion, improving glucose uptake through GLUT receptor upregulation, reducing oxidative stress and inflammation, promoting wound healing, reducing HbA1C, reducing HOMA‐IR index, and decreased mRNA expressions ...
Oliver Dean John, Nur Damia Iwani Zulkiflee, Siti Raihanah Shafie, Ramlah George, Melonney Patrick   +4 more
wiley   +1 more source

Cardioprotective effects of sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase 4 inhibitor in type 2 diabetes: A meta-analysis of comparative safety and efficacy

SAGE Open Medicine
Background: Sodium glucose cotransporter 2 inhibitors are recommended for the treatment of heart failure due to their cardioprotective effects, despite primarily being used as antidiabetic medications. However, the comparative profile of two antidiabetic
Abhigan Babu Shrestha, Anupam Halder, Kripa Rajak, Saroj Kumar Jha, Ramesh Lamichhane, Arefin Naher Oishee, Nayanika Tummala Chowdary, Pashupati Pokharel, Sajina Shrestha, Lukash Adhikari, Bikash Adhikari, Aman Rajak, Jalal Haider Khan, Nischal Mainali   +13 more
doaj   +1 more source

Adipose‐derived mesenchymal stem cell injection into the KI10 acupoint mitigates cartilage damage in KOA rats through PGE2‐mediated α7nAChR/NF‐κB pathway

Animal Models and Experimental Medicine, EarlyView.
In our research, KOA rat models were established and treated with ADSC injection into the KI10 acupoint. Pain relief, behavioral function, and joint structural improvements were systematically assessed using ethological tests, imaging, histopathological staining, transmission electron microscopy, and molecular analyses.
Mengwei Dong, Wenfang Li, Wanpeng Yang, Te Ba, Nan Nan, Yang Liu, Jing Han, Huiqin Hao   +7 more
wiley   +1 more source

PERsonalised Medicine for Intensification of Treatment (PERMIT) in type 2 diabetes mellitus: a target trial emulation from routine data

Health Technology Assessment
Background Evidence is required on the relative effectiveness of sulphonylureas, dipeptidyl peptidase-4 inhibitors or sodium–glucose cotransporter 2 inhibitors added to metformin for people with type 2 diabetes mellitus.
David G Lugo-Palacios, Patrick Bidulka, Paul Charlton, Bill Huston, Anna Carnegie, Orlagh Carroll, Stephen O’Neill, Amanda I Adler, Anirban Basu, Richard J Silverwood, Andrew H Briggs, Liam Smeeth, Ian J Douglas, Kamlesh Khunti, Richard Grieve   +14 more
doaj   +1 more source

Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review

Терапевтический архив
The review addresses publications on genetic polymorphisms that potentially impact the effectiveness of therapy with hypoglycemic drugs of the dipeptidyl peptidase-4 inhibitor group.
Iuliia G. Samoilova, Olga E. Vaizova, Anastasia E. Stankova, Mariia V. Matveeva, Daria V. Podchinenova, Dmitry A. Kudlay, Anastasiia A. Borozinets, Tatyana A. Filippova, Ivan R. Grishkevich, Anastasia V. Partala, Diana A. Gerasimova   +10 more
doaj   +1 more source

Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease

Cardiovascular Diabetology, 2012
Background Diabetic patients present with an accelerated atherosclerotic process and an increased risk for future cardiovascular events. In addition to the risk imposed by the disease itself, pharmacological treatment adds also a sizable risk, especially
Klempfner Robert, Leor Jonathan, Tenenbaum Alexander, Fisman Enrique Z, Goldenberg Ilan   +4 more
doaj   +1 more source

Inhibitors of dipeptidyl-peptidase-4: obvious and probable (literature review)

Медицинский совет, 2022
The purpose of the presented literature review was an attempt to sum up current estimates of the effect of the use of dipeptidyl peptidase-4 inhibitors (iDPP-4) in the algorithms of both traditional (diabetes mellitus) and a number of alternative ...
E. A. Ortenberg, L. A. Suplotova
doaj   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source